Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,311
  • Shares Outstanding, K 2,782
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,350 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1400 +2.63%
on 12/13/24
1.4600 -19.86%
on 11/29/24
-0.0700 (-5.65%)
since 11/18/24
3-Month
1.1400 +2.63%
on 12/13/24
4.0360 -71.01%
on 09/19/24
-2.7800 (-70.38%)
since 09/18/24
52-Week
1.1400 +2.63%
on 12/13/24
17.1125 -93.16%
on 03/20/24
-13.5875 (-92.07%)
since 12/18/23

Most Recent Stories

More News
Theriva Biologics Receives FDA Guidance for Phase 3 Study of VCN-01 in Metastatic Pancreatic Adenocarcinoma

Theriva Biologics received FDA guidance on VCN-01's Phase 3 study for metastatic pancreatic cancer treatment, optimizing trial design.Quiver AI SummaryTheriva Biologics has announced the outcomes of a...

TOVX : 1.1700 (-1.68%)
Therivaâ„¢ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

TOVX : 1.1700 (-1.68%)
Therivaâ„¢ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

TOVX : 1.1700 (-1.68%)
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

TOVX : 1.1700 (-1.68%)
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

TOVX : 1.1700 (-1.68%)
Therivaâ„¢ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

TOVX : 1.1700 (-1.68%)
S&P Futures Tick Lower Ahead of Powell Speech, Chip War Heats Up

September S&P 500 futures (ESU23) are trending down -0.15% this morning as a report on potential new restrictions on the export of artificial intelligence chips to China weighed on sentiment, while investors...

ESU23 : 4,491.72s (-0.32%)
MSFT : 437.39 (-3.76%)
AAPL : 248.05 (-2.14%)
AMZN : 220.52 (-4.60%)
META : 597.19 (-3.59%)
DAL : 58.88 (-3.17%)
SNOW : 162.59 (-4.81%)
WBA : 9.70 (-2.71%)
RIDE : 2.20 (+2.33%)
MU : 103.90 (-4.33%)
GIS : 63.91 (-3.06%)
CA.FP : 13.765 (+0.18%)

Business Summary

Theriva Biologics Inc. is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company's lead candidate includes VCN-01, SYN-004 and SYN-020. Theriva Biologics Inc., formerly known as Synthetic Biologics Inc., is based in ROCKVILLE,...

See More

Key Turning Points

3rd Resistance Point 1.2633
2nd Resistance Point 1.2367
1st Resistance Point 1.2033
Last Price 1.1700
1st Support Level 1.1433
2nd Support Level 1.1167
3rd Support Level 1.0833

See More

52-Week High 17.1125
Fibonacci 61.8% 11.0110
Fibonacci 50% 9.1262
Fibonacci 38.2% 7.2415
Last Price 1.1700
52-Week Low 1.1400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar